A detailed history of Newbridge Financial Services Group, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Newbridge Financial Services Group, Inc. holds 621 shares of HALO stock, worth $41,277. This represents 0.01% of its overall portfolio holdings.

Number of Shares
621
Holding current value
$41,277
% of portfolio
0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 19, 2025

BUY
$47.91 - $70.14 $29,752 - $43,556
621 New
621 $32,000
Q1 2024

Apr 24, 2024

BUY
$33.68 - $41.95 $336 - $419
10 New
10 $0

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $9.26B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Newbridge Financial Services Group, Inc. Portfolio

Follow Newbridge Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Newbridge Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Newbridge Financial Services Group, Inc. with notifications on news.